Role of serum N-terminal pro-brain natriuretic peptide measurement in diagnosis of cardiac involvement in patients with anderson-fabry disease

American Journal of Cardiology

Volumn 111, Issue 1, 2013, Pages 111-117

  Coats, Caroline J ^a   Parisi, Valentina ^a   Ramos, Monica ^a   Janagarajan, Kalaiarasi ^a   O'Mahony, Constantinos ^a   Dawnay, Anne ^a   Lachmann, Robin H ^b   Murphy, Elaine ^b   Mehta, Atul ^c   Hughes, Derralynn ^c   Elliott, Perry M ^a  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CREATININE;

ADULT; AGE; AGED; ARTICLE; CARDIOMYOPATHY; CLINICAL EVALUATION; CREATININE BLOOD LEVEL; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FABRY DISEASE; FEMALE; HEART INDEX; HEART LEFT ATRIUM; HEART VOLUME; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REST;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BIOPSY; CROSS-SECTIONAL STUDIES; DIAGNOSIS, DIFFERENTIAL; ECHOCARDIOGRAPHY, DOPPLER; ELECTROCARDIOGRAPHY; FABRY DISEASE; FEMALE; FOLLOW-UP STUDIES; GREAT BRITAIN; HEART VENTRICLES; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; INCIDENCE; MALE; MICROSCOPY, ELECTRON; MIDDLE AGED; MYOCYTES, CARDIAC; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROGNOSIS; PROSPECTIVE STUDIES; PROTEIN PRECURSORS; RISK FACTORS; VENTRICULAR FUNCTION, LEFT; YOUNG ADULT;

EID: 84871000417     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2012.08.055     Document Type: Article

References (30)

1. A. Linhart, C. Kampmann, J.L. Zamorano, G. Sunder-Plassmann, M. Beck, A. Mehta, P.M. Elliott European FOS Investigators Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey Eur Heart J 28 2007 1228 1235
2. F. Weidemann, F. Breunig, M. Beer, J. Sandstede, O. Turschner, W. Voelker, G. Ertl, A. Knoll, C. Wanner, and J.M. Strotmann Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study Circulation 108 2003 1299 1301
3. M. Imbriaco, A. Pisani, L. Spinelli, A. Cuocolo, G. Messalli, E. Capuano, M. Marmo, R. Liuzzi, B. Visciano, B. Cianciaruso, and M. Salvatore Effects of enzyme-replacement therapy in patients with Anderson-Fabry disease: a prospective long-term cardiac magnetic resonance imaging study Heart 95 2009 1103 1107
4. R. Schiffmann, J.B. Kopp, H.A. Austin III, S. Sabnis, D.F. Moore, T. Weibel, J.E. Balow, and R.O. Brady Enzyme replacement therapy in Fabry disease: a randomized controlled trial JAMA 285 2001 2743 2749
5. C.M. Eng, N. Guffon, W.R. Wilcox, D.P. Germain, P. Lee, S. Waldek, L. Caplan, G.E. Linthorst, R.J. Desnick International Collaborative Fabry Disease Study Group Safety and efficacy of recombinant human α-galactosidase A replacement in Fabry disease N Engl J Med 345 2001 9 16
6. A.S. Maisel, P. Krishnaswamy, R.M. Nowak, J. McCord, J.E. Hollander, P. Duc, T. Omland, A.B. Storrow, W.T. Abraham, A.H. Wu, P. Clopton, P.G. Steg, A. Westheim, C.W. Knudsen, A. Perez, R. Kazanegra, H.C. Herrmann, P.A. McCullough Breathing Not Properly Multinational Study Investigators Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure N Engl J Med 347 2002 161 167
7. R. Berger, M. Huelsman, K. Strecker, A. Bojic, P. Moser, B. Stanek, and R. Pacher B-type natriuretic peptide predicts sudden death in patients with chronic heart failure Circulation 105 2002 2392 2397
8. R.W. Troughton, C.M. Frampton, T.G. Yandle, E.A. Espiner, M.G. Nicholls, and A.M. Richards Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations Lancet 355 2000 1126 1130
9. A. Nguyen Dinh Cat, B. Escoubet, V. Agrapart, V. Griol-Charhbili, T. Schoeb, W. Feng, E. Jaimes, D.G. Warnock, and F. Jaisseret Cardiomyopathy and response to enzyme replacement therapy in a male mouse model for Fabry disease PLoS One 7 2012 e33743 1-9
10. M.Á. Torralba-Cabeza, S. Olivera, D.A. Hughes, G.M. Pastores, R.N. Mateo, and J.I. Pérez-Calvo Cystatin C and NT-proBNP as prognostic biomarkers in Fabry disease Mol Genet Metab 104 2011 301 307
11. M. Beck The Mainz Severity Score Index (MSSI): development and validation of a system for scoring the signs and symptoms of Fabry disease Acta Paediatr Suppl 95 2006 43 46
12. National Kidney Foundation K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification Am J Kidney Dis 39 2002 S1 266
13. M. Sokolow, and T.P. Lyon The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads Am Heart J 37 1949 161 186
14. P.N. Casale, R.B. Devereux, D.R. Alonso, E. Campo, and P. Kligfield Improved sex-specific criteria of left ventricular hypertrophy for clinical and computer interpretation of electrocardiograms: validation with autopsy findings Circulation 75 1987 565 572
15. N.B. Schiller, P.M. Shah, M. Crawford, A. DeMaria, R. Devereux, H. Feigenbaum, H. Gutgesell, N. Reichek, D. Sahn, and I. Schnittger Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms J Am Soc Echocardiogr 2 1989 358 367
16. R.M. Lang, M. Bierig, R.B. Devereux, F.A. Flachskampf, E. Foster, P.A. Pellikka, M.H. Picard, M.J. Roman, J. Seward, J.S. Shanewise, S.D. Solomon, K.T. Spencer, M.S. Sutton, W.J. Stewart Chamber Quantification Writing Group; American Society of Echocardiography's Guidelines and Standards Committee; European Association of Echocardiography Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology J Am Soc Echocardiogr 18 2005 1440 1463
17. R.B. Devereux, and N. Reichek Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method Circulation 55 1977 613 618
18. W.J. Paulus, C. Tschöpe, J.E. Sanderson, C. Rusconi, F.A. Flachskampf, F.E. Rademakers, P. Marino, O.A. Smiseth, G. De Keulenaer, A.F. Leite-Moreira, A. Borbély, I. Edes, M.L. Handoko, S. Heymans, N. Pezzali, B. Pieske, K. Dickstein, A.G. Fraser, and D.L. Brutsaert How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology Eur Heart J 28 2007 2539 2550
19. V.K. Munagala, S.J. Jacobsen, D.W. Mahoney, R.J. Rodeheffer, K.R. Bailey, and M.M. Redfield Association of newer diastolic function parameters with age in healthy subjects: a population-based study J Am Soc Echocardiogr 16 2003 1049 1056
20. C. Tei, K.S. Dujardin, D.O. Hodge, R.A. Kyle, A.J. Tajik, and J.B. Seward Doppler index combining systolic and diastolic myocardial performance: clinical value in cardiac amyloidosis J Am Coll Cardiol 28 1996 658 664
21. A. Linhart, and P.M. Elliott The heart in Anderson-Fabry disease and other lysosomal storage disorders Heart 93 2007 528 535
22. M.N. Sheppard The heart in Fabry's disease Cardiovasc Pathol 20 2009 8 14
23. Y.A. Zarate, and R.J. Hopkin Fabry's disease Lancet 372 2008 1427 1435
24. T. Lucke, W. Hoppner, E. Schmidt, S. Illsinger, and A.M. Das Fabry disease: reduced activities of respiratory chain enzymes with decreased levels of energy-rich phosphates in fibroblasts Mol Genet Metab 82 2004 93 97
25. P.M. Elliott, H. Kindler, J.S. Shah, B. Sachdev, O.E. Rimoldi, R. Thaman, M.T. Tome, W.J. McKenna, P. Lee, and P.G. Camici Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A Heart 92 2006 357 560
26. O. Lidove, M.L. West, G. Pintos-Morell, R. Reisin, K. Nicholls, L.E. Figuera, R. Parini, L.R. Carvalho, C. Kampmann, G.M. Pastores, and A. Mehta Effects of enzyme replacement therapy in Fabry disease - a comprehensive review of the medical literature Genet Med 12 2010 668 679
27. M. Beer, F. Weidemann, F. Breunig, A. Knoll, S. Koeppe, W. Machann, D. Hahn, C. Wanner, J. Strotmann, and J. Sandstede Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy Am J Cardiol 97 2006 1515 1518
28. M. Pieroni, C. Chimenti, R. Ricci, P. Sale, M.A. Russo, and A. Frustaci Early detection of Fabry cardiomyopathy by tissue Doppler imaging Circulation 107 2003 1978 1984
29. B.S. Edwards, R.S. Zimmerman, T.R. Schwab, D.M. Heublein, and J.C. Burnett Jr. Atrial stretch, not pressure, is the principal determinant controlling the acute release of atrial natriuretic factor Circ Res 62 1988 191 195
30. C. Chimenti, N. Hamdani, N.M. Boontje, F. DeCobelli, A. Esposito, J.G. Bronzwaer, G.J. Stienen, M.A. Russo, W.J. Paulus, A. Frustaci, and J. van der Velden Myofilament degradation and dysfunction of human cardiomyocytes in Fabry disease Am J Pathol 172 2008 1482 1490